Literature DB >> 25961532

KIT gene mutations in gastrointestinal stromal tumor.

Weiming Kang, Changzhen Zhu, JianChun Yu1, Xin Ye, ZhiQiang Ma.   

Abstract

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. It arises in the stomach, small intestine, colon, rectum and esophagus. KIT gene mutation is a feature of GIST, in addition to PDGFRA gene mutation. KIT gene mutations have been observed to be involved in the development of GIST, its recurrence after surgery and chemotherapy resistance in GIST. Exons 13, 17, 9, and mainly exon 11 are concerned in these biological behaviors of GIST. In this review, we will discuss on the involvement of KIT gene mutations in the tumorigenesis, recurrence and chemotherapeutic resistance of GIST.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25961532     DOI: 10.2741/4346

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  6 in total

1.  BLU-285-the breakthrough in treatment of patients with aggressive systemic mastocytosis and gastrointestinal stromal tumor.

Authors:  Regine Schneider-Stock
Journal:  Ann Transl Med       Date:  2018-06

2.  CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.

Authors:  Ke Cao; Minhuan Li; Ji Miao; Xiaofeng Lu; Xing Kang; Hao Zhu; Shangce Du; Xue Li; Qian Zhang; Wenxian Guan; Ying Dong; Xuefeng Xia
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

3.  The relationship between the number of circulating tumor cells and the prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Zhipeng Ren; Xiaobin Hou; Zhiqiang Xue; Lianbin Zhang; Bo Wang; Jiaxin Wen; Xiangyang Chu
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 4.  The contributions of extrachromosomal DNA elements in neoplasm progression.

Authors:  Jiawei Hong; Shusen Zheng; Donghai Jiang
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity.

Authors:  Chris Liang; Xiaobin Yuan; Zhilin Shen; Yang Wang; Lieming Ding
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

Review 6.  Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors.

Authors:  Xiangchen Hu; Zhe Wang; Peng Su; Qiqi Zhang; Youwei Kou
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.